Drug Discovery Weekly — 2026-03-30

---

FDA & Regulatory Decisions

• Orforglipron (Eli Lilly): Upcoming PDUFA — Q2 2026. The oral GLP-1 receptor agonist for obesity is among the most closely watched verdicts of the quarter; its approval would intensify oral vs. injectable competition in the weight-loss market, which analysts consider a pivotal inflection point for the class.

• Cytisinicline (Achieve Life Sciences): Upcoming PDUFA — Q2 2026. A plant-derived partial nicotinic agonist for smoking cessation is under review; positive outcome would add a novel non-nicotine-replacement option to a market dominated by varenicline generics.

• Multiple CNS & HIV Candidates: Neurology and infectious disease decisions expected Q2 2026. Drugs targeting Alzheimer's disease agitation, focal segmental glomerulosclerosis, hematological malignancies, and HIV-1 are all under active FDA review with PDUFA dates falling this quarter, signaling a potentially transformative period for these therapeutic areas.

---

Clinical Trial Milestones

• Unnamed Biogen Lupus Drug — Phase 2 (Biogen): Met primary endpoint — positive mid-stage skin clearance data. Results published this morning show meaningful improvement in skin manifestations in lupus patients; the drug now advances toward a pivotal study design discussion, strengthening Biogen's pipeline in autoimmune disease following years of high-profile setbacks.

• Takeda Psoriasis Candidate — Phase 3 (Takeda): Competitive data readout reported today. Takeda released Phase 3 psoriasis trial results that analysts describe as competitive within the IL-17/IL-23 class landscape; detailed data points are pending full publication, but the readout positions Takeda for a potential regulatory submission in moderate-to-severe plaque psoriasis.

• SGT-003 — Phase 1/2 INSPIRE DUCHENNE (Solid Biosciences): Interim positive update. Solid Biosciences reported positive interim clinical data for its gene therapy SGT-003 in Duchenne muscular dystrophy; the company has also reached FDA alignment on the design for the subsequent randomized, double-blind, placebo-controlled Phase 3 trial (IMPACT DUCHENNE), marking a significant milestone for a rare disease community with high unmet need.

---

Deals & M&A

• Otsuka Pharmaceutical + Transcend Therapeutics: Acquisition. $700 million upfront cash consideration. Expected to close Q2 2026, subject to customary conditions; this deal expands Otsuka's therapeutic portfolio and signals continued Japanese pharma appetite for U.S. biotech assets targeting CNS and specialty disease areas.

• Merck + Terns Pharmaceuticals: Acquisition. ~$6.7 billion (~$53.00 per share, all-cash). Deal announced approximately one week ago and moving toward close; Merck acquires Terns' pipeline, which includes a thyroid hormone receptor beta agonist for metabolic liver disease (MASH), broadening Merck's footprint in one of the most competitive emerging therapeutic areas.

• Eli Lilly + Ventyx Biosciences: Acquisition (announced January 2026, on track for close). ~$1.2 billion ($14.00 per share, all-cash). Lilly acquires Ventyx's oral small-molecule pipeline targeting inflammatory diseases, including a selective NLRP3 inhibitor, reinforcing its strategy to build oral-first immunology assets beyond its GLP-1 franchise.

---

Pipeline & Discovery Spotlight

Today's most compelling preclinical signal comes from the growing convergence of Eli Lilly's "triple-G" retatrutide and the next wave of GLP-based pharmacology. Lilly's Phase 3 data on retatrutide — a GIP/GLP-1/glucagon triple receptor agonist — delivered striking results reported roughly two weeks ago, with weight loss figures that may substantially exceed those of approved dual agonists. The mechanistic rationale is straightforward: by simultaneously activating glucagon receptors in addition to GIP and GLP-1 pathways, retatrutide drives greater caloric expenditure on top of appetite suppression, potentially enabling weight reductions approaching or exceeding those seen with bariatric surgery.

Why does this matter for the field? It validates the "multi-agonist" design principle as a viable pharmacological strategy — not merely incremental dosing — and is already driving academic and industry efforts to explore quad-agonist constructs and combination approaches with amylin analogs. The implications extend well beyond obesity: retatrutide's glucagon component is also under investigation for its hepatoprotective effects in MASH (metabolic dysfunction-associated steatohepatitis), potentially giving Lilly a single molecule bridging two of the largest unmet-need markets in metabolic medicine. Competitive implications for semaglutide and tirzepatide are significant and are expected to shape Q2 formulary negotiations across major payers.

---

What to Watch Next Week

• Orforglipron PDUFA (Eli Lilly): April/Q2 2026 target window — FDA decision on the first oral GLP-1 for obesity; approval would reshape the weight-loss competitive landscape immediately.
• Alzheimer's Agitation NDA Decision: April 2026 expected — FDA ruling on candidate for Alzheimer's-related agitation, a condition with no currently approved pharmacotherapy; could open a large, underserved indication.
• HIV-1 Oral Regimen NDA: April 2026 expected — FDA verdict on the doravirine/islatravir (DOR/ISL) single-tablet regimen from Merck; positive Phase 3 data showed non-inferiority to BIC/FTC/TAF in treatment-naïve adults.
• Otsuka–Transcend Deal Close: Q2 2026 target — watch for Hart-Scott-Rodino clearance timeline and any pipeline disclosures from Transcend upon close.
• Merck–Terns MASH Data Update: Following acquisition momentum, market expects further MASH clinical data disclosure, particularly for Terns' THRβ agonist, within the next several weeks.

---

Reader Action Items

• Competitive Intelligence — Obesity/Metabolic: The convergence of retatrutide's Phase 3 results and orforglipron's approaching PDUFA creates an immediate need to re-model payer contracting strategies and portfolio positioning. Companies with single-mechanism GLP-1 assets should accelerate differentiation narratives — either through combination strategies or disease-specific subgroup data — before Lilly potentially holds two approved entries in the oral and injectable segments simultaneously.

• M&A Signal — Autoimmune & Rare Disease: Three confirmed acquisitions (Otsuka/Transcend, Merck/Terns, Lilly/Ventyx) in under 90 days, plus Biogen's lupus mid-stage success today, underscore that autoimmune, rare disease, and metabolic assets with clean Phase 2 data remain premium acquisition targets. Business development teams should benchmark current pipeline valuations against the $1.2B–$6.7B deal range now being set as the reference tier for pre-Phase-3 assets.